Results 41 to 50 of about 557 (132)
British Journal of Pharmacology, EarlyView.The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral +3 more
wiley +1 more source
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
, 2021 Introduction: Obesity is a growing threat to public health, increasing risks of numerous diseases and mortality, and impairing quality of life. If current trends continue, more than 1.1 billion individuals will have obesity in 2030, corresponding to ...
Jepsen, Mathies M. +1 more
core +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Incretin‐based pharmacotherapy was initially developed to improve glucose‐dependent insulin secretion and glycaemic control in type 2 diabetes, but its clinical interpretation has expanded substantially with cardiovascular outcome trials, kidney outcome data, obesity studies and next‐generation polyagonist development.
Ferenc Sztanek +3 more
wiley +1 more source
Rethinking Global Obesity Guidelines: Integrating Evidence, Equity and Precision (2014–2026)
Obesity Reviews, EarlyView.Challenges and evidence in obesity guidelines. ABSTRACT Obesity remains a global health crisis characterized by substantial heterogeneity in diagnosis, management, and policy implementation. Although numerous national and international clinical practice guidelines have been published over the past decade, their translation into evidence‐based and ...
Rosero‐Revelo Ricardo +13 more
wiley +1 more source
The Journal of Physiology, EarlyView.Abstract figure legend During GLP‐1RA treatment reduced appetite and energy intake, delayed gastric emptying, decreased visceral fat mass and improved glycaemic control contribute to weight loss. After treatment cessation these benefits are partially or completely reversed, resulting in weight regain, accompanied by increased appetite and energy intake,
Camille E. M. Piguet +2 more
wiley +1 more source
Effect of GLP‐1 receptor agonist on nutrient intake: A narrative review
Nutrition in Clinical Practice, Volume 41, Issue 5, Page 1308-1317, October 2026.Abstract Humans have a primitive defense mechanism called metabolic adaptation that slows voluntary weight loss. It works by downregulating hormones that reduce food intake and by lowering the metabolic rate. Second‐generation GLP‐1 receptor agonists, such as semaglutide or tirzepatide, promote weight loss by targeting this hormonal system to control ...
Ken Fujioka
wiley +1 more source
Nutrition in Clinical Practice, Volume 41, Issue 5, Page 1318-1333, October 2026.Abstract Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 receptor agonists have transformed the management of type 2 diabetes and obesity. Gastrointestinal (GI) adverse events are the most common limitation of these therapies and a leading cause of discontinuation ...
Vikash Singhani +6 more
wiley +1 more source
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Indian Journal of Endocrinology and MetabolismObesity is a heterogeneous, complex, and chronic disease that has a detrimental impact on disability-adjusted life years across the globe. Recent advancements in our understanding of gut-brain communication at the molecular level have driven the ...
Wael R. Sidrak +2 more
doaj +1 more source
Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide
Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8946-8954, October 2026.ABSTRACT Aims Zenagamtide is a novel, unimolecular glucagon‐like peptide‐1 and amylin receptor agonist in development for weight management and Type 2 diabetes. This study investigated the pharmacokinetic (PK) properties, safety and tolerability of zenagamtide in participants with various degrees of renal impairment versus participants with normal ...
Lykke Ida Kaas Oldenburg +6 more
wiley +1 more source
Central nervous system pathways targeted by amylin in the regulation of food intake [PDF]
Amylin is a peptide hormone co-released with insulin from pancreatic β-cells during a meal and primarily serves to promote satiation. While the caudal hindbrain was originally implicated as a major site of action in this regard, it is becoming ...
Le Foll, Christelle; https://orcid.org/ +1 more
core +1 more source